Debate: MSI High Colon Cancer - Immunotherapy

October 8, 2022, Revolution Cancer International Molecular Tumor Board - Merck, MSI-High CRC, NTRKПодробнее

Debate: MSI High Colon Cancer - Upfront ChemotherapyПодробнее

Immunotherapy for MSI High Colon CancerПодробнее

Debate: Can biomarkers beyond MSI direct immunotherapy in GI malignancies? - NoПодробнее

Debate: Optimal salvage therapy for refractory colon cancer? - TAS102 or RegorafenibПодробнее

$Debate: Optimal salvage therapy for refractory colon cancer? - TAS102 or Regorafenib$

Hereditary colorectal cancer and gastric cancerПодробнее